Answers are grounded in this paper and cite their sources.
Byrsonima intermedia leaves are traditionally used to treat inflammatory and infectious conditions, but their bioactive constituents remain incompletely characterised. This study linked the UHPLC–HRMS/MS profile of the ethyl acetate fraction (EAF) of B. intermedia leaves to antioxidant, antibacterial and cytotoxic evaluations. Sixteen phenolic compounds, predominantly flavonoids and flavan-3-ols, were putatively annotated. Among the plant samples, the EAF showed the strongest overall antioxidant activity (DPPH IC50 4.8 µg/mL; 87.5% phosphomolybdenum activity; 94.7% protection against deoxyribose degradation) and its highest antibacterial effect against Escherichia coli. It was also cytotoxic to U87MG, HT29, U937, THP-1 and H460 cells (IC50 22.7–53.2 µg/mL), although less active than doxorubicin and with low selectivity towards non-tumour RAW 264.7 macrophages. By associating a 16-compound profile with multiple biological responses, this work provides a basis for prioritising B. intermedia constituents for isolation and mechanistic studies.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: